Parallel RNAi and compound screens identify the PDK1 pathway as a target for tamoxifen sensitization.

@article{Iorns2009ParallelRA,
  title={Parallel RNAi and compound screens identify the PDK1 pathway as a target for tamoxifen sensitization.},
  author={Elizabeth Iorns and Christopher J Lord and Alan Ashworth},
  journal={The Biochemical journal},
  year={2009},
  volume={417 1},
  pages={361-70}
}
Tamoxifen is the most commonly used drug to treat breast cancer and acts by blocking ERalpha (oestrogen receptor alpha) signalling. Although highly effective, its usefulness is limited by the development of resistance. Given this, strategies that limit resistance by sensitizing cells to tamoxifen may be of use in the clinic. To gain insight into how this might be achieved, we used chemical and genetic screens to identify targets and small-molecule inhibitors that cause tamoxifen sensitization… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 27 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 32 references

Similar Papers

Loading similar papers…